MHI-RJ-AVIATION-GROUP
20.7.2022 18:34:04 CEST | Business Wire | Press release
MHI RJ Aviation Group (MHIRJ) has announced today at the Farnborough Air Show the signing of an agreement with Air Nostrum Engineering and Maintenance (ANEM), appointing them as a MHIRJ Authorized Service Facility (ASF) in Europe. This agreement marks an important step in expanding MHIRJ’s service network internationally, allowing MHIRJ to extend, in collaboration with ANEM, the same levels of service that customers in North America receive through its wholly owned service centers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220720005641/en/
This agreement expands MHIRJ’s existing ASF support structure in Europe, introducing diversity and additional capacity to the existing network. ANEM’s addition will serve to meet the growing demands of the market, offering a wider array of availability and options for the European sector as well as for MHIRJ customers worldwide.
Based in Valencia (Spain), ANEM is part of the group of companies fully owned by the same shareholders of the airline Air Nostrum. ANEM currently serves as MRO and aircraft maintenance services provider for multiple airlines based in Europe, Africa, and Latin America. Air Nostrum has been operating CRJ Series aircraft since the year 1998 and currently operates the largest CRJ Series fleet in Europe, accounting for 37 CRJ Series aircraft. Air Nostrum is a ten-time MHIRJ Customer Reliability Award winner and a multiple time winner of the ERA Airline of the Year. Their vast operational experience will provide a first-rate base to support the CRJ Series fleet in Europe and across the world. Combining the strengths of ANEM and MHIRJ will bring forth our world-class Aftermarket network to the next level, providing our customers the full suite of MRO services.
Hiro Yamamoto, President and CEO of MHIRJ, commented “We are extremely proud to announce this agreement with Air Nostrum which will benefit customers in the European region, allowing them to access strong MRO support close to home. Reliability has always been the CRJ Series fleet’s strong suit; this agreement maintains that reliability and ensures an even stronger commitment to our customers.”
“ANEM brings a versatile set of capabilities that substantially enhances the CRJ Series MRO support for our European and International customers. As the maintenance arm of the largest CRJ Series carrier in Europe; our strategic collaboration with ANEM favorably positions us to collectively grow and expand support outside of North America,” commented Ismail Mokabel, Senior Vice-President and Head of Aftermarket at MHIRJ.
Amel Belkhamsa, Head of Aftermarket Commercial Services and Spare Parts Operations at MHIRJ, added “This is the first step in broadening our relationship with Air Nostrum to provide support to MHIRJ’s customers outside of North America. We wanted to find an MRO with a large range of capabilities to open the door to even more potential future collaboration, such as in the areas of material support and field response services, to ensure that all our international customers receive the best support available.”
Miguel Falcon, Vice Chairman of Air Nostrum and ANEM, said: “We are delighted to strengthen our cooperation with MHIRJ via this ASF agreement as its next Authorized MRO. We have 24 years of experience with the CRJ Series and have provided exceptional reliability for our customers, and this is due largely to the great relationship that we have with MHIRJ.”
Fermin Tirado, General Manager of ANEM, commented: “Thanks to the dedication and exceptional skills of our team members at ANEM, we´re quite pleased to sign this ASF agreement with MHIRJ that enhances our long-established partnership, allows us to increase the number of employees in ANEM, and grow our capacity for our airline customers.”
About Air Nostrum Group
Air Nostrum Group comprises different companies related to air transport and mobility including airlines, high speed railway transportation and firefighting, as well as related services companies: maintenance, training, flight support etc. The Group flagship, Air Nostrum Líneas Aereas, based in Spain, operates over 70,000 flights carrying more than 4,7 million passengers each year, being the leading regional aviation company in Spain and one of the largest in Europe. It operates for the Iberia Group under the Iberia Regional Air Nostrum brand, has sales over 500 million euros and employs more than 1,400 people.
About ANEM
ANEM is a PART 145 MRO (ES.145.060) and CAMO (ES.CAMO.059) company that arises from the split of AIR NOSTRUM’s business activities. ANEM performs the whole maintenance of the Air Nostrum’s Group fleets, including Air Nostrum, Hibernian, Melair, Paranair and PLYSA. These fleets are: CRJ200, CRJ900, CRJ1000, ATR72-600, and THRUSH S2R-T660. ANEM has a modern Hangar in Valencia Airport in order to cover all maintenance phases of the Air Nostrum’s Group and other operators’ fleets.
About MHI RJ Aviation Group
MHI RJ Aviation Group (MHIRJ) provides comprehensive critical operational, engineering and customer support solutions including maintenance, refurbishment, technical publications, marketing and sales activities for the global regional aircraft industry. Headquartered in Montréal, Canada, and bolstered by an Aerospace Engineering Centre, MHIRJ’s network of service centers, support offices and parts depots are positioned in important aviation hubs in Canada, the U.S. and Germany. A wholly owned subsidiary of Mitsubishi Heavy Industries, Ltd., MHI RJ Aviation Group includes MHI RJ Aviation ULC (Canada), MHI RJ Aviation Inc. (U.S.A.) and MHI RJ Aviation GmbH (Germany).
WE ARE HIRING. Visit mhirj.com/en/careers to know more.
For more information about MHI RJ Aviation Group, please visit: mhirj.com or follow our insights and stories on wingspan.mhirj.com
About MHI Group
Mitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life, and ensure a safer world.
For more information, please visit www.mhi.com or follow our insights and stories on www.spectra.mhi.com
*CRJ, CRJ Series and MHIRJ are trademarks of MHI RJ Aviation ULC or its affiliates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005641/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom